Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337626 | 0.95 | PTPN1 (0.41) | PTPN1CYP2A6CYP1A2SLC6A4CYP3A4 | |
| SCHEMBL812047 | 0.77 | ALDH1A1 (0.44) | PTPN1CYP2D6SIGMAR1 | |
| SCHEMBL812265 | 0.74 | KIF11 (0.52) | — | |
| SCHEMBL295494 | 0.73 | LMNA (0.40) | CYP1A2CYP3A4CYP2D6KCNH2TDP1 | |
| SCHEMBL18936186 | 0.72 | PTPN1 (0.55) | PTPN1CYP2A6CYP1A2CYP3A4TDP1 | |
| SCHEMBL16439916 | 0.72 | PTPN1 (0.55) | PTPN1CYP2A6CYP1A2CYP3A4TDP1 | |
| SCHEMBL4427051 | 0.72 | KIF11 (0.42) | CYP3A4KCNH2TDP1 | |
| SCHEMBL30706974 | 0.72 | PTPN1 (0.59) | PTPN1CYP2A6CYP1A2CYP3A4TDP1 | |
| SCHEMBL1538767 | 0.72 | PTPN1 (0.59) | PTPN1CYP2A6CYP1A2CYP3A4TDP1 | |
| SCHEMBL30985267 | 0.72 | PTPN1 (0.59) | PTPN1CYP2A6CYP1A2CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063205-B2 | Method for producing 2-oxazoline analogue or 1,3-oxazine analogue | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1956012-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | National University Corporation Hokkaido University (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | OXA1L, SULT1A1, DAO | PTPN1 3271/4885CYP2A6 832/4885CYP1A2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.